NCT00711854|CompletedPhase 4
Loading search results
Sponsor study identifier
interventional
150
1 country
1
Study Start
January 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2013
Actual (reported)Study Completion
February 2014
Actual (reported)MRSA infections often require systemic antibiotic therapy and represent an important healthcare burden. Currently available treatment options are either only available in parenteral form (vancomycin) or expensive (linezolid). Thus, there is an urgent, unmet need to better investigate in-expensive but highly active alternatives to currently recommended standard treatment options. The purpose of the proposed study is to test the hypothesis that a combination of TMP-SMX and rifampicin is not inferior to linezolid for treatment of MRSA infections.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2014
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 3, 2008
Actual (reported)July 9, 2008
Actual (reported)January 2009
Date type not reportedThis date has not been verified as actual or estimated.
December 2013
Actual (reported)February 2014
Actual (reported)Bacteriological and clinical cure
6 weeks
Treatment costs
6 weeks
trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin
Linezolid
Geneva University Hospitals
Geneva, 1211, Switzerland
Harbarth S, von Dach E, Pagani L, Macedo-Vinas M, Huttner B, Olearo F, Emonet S, Uckay I. Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. J Antimicrob Chemother. 2015 Jan;70(1):264-72. doi: 10.1093/jac/dku352. Epub 2014 Sep 10.
Stephan Harbarth, MD, MS
University Hospital, Geneva
150 participants (actual enrollment reported by the registry).
First Submitted
July 3, 2008
First Posted
July 9, 2008
Study Start
January 2009
Date type not reportedThis date has not been verified as actual or estimated.
Pregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis
Rifampicin (600 mg IV or PO once daily)
Contact the study team to confirm eligibility.
Primary Completion
December 2013
Actual (reported)Study Completion
February 2014
Actual (reported)Last Updated
August 5, 2014
Record last verified: 2014-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: